Neoadjuvant treatment for malignant and metastatic cutaneous melanoma

Cochrane Database of Systematic Reviews

Volumn 2018, Issue 3, 2018, Pages

  Gorry, Claire ^a   Mccullagh, Laura ^a   O'Donnell, Helen ^a   Barrett, Sarah ^a   Schmitz, Susanne ^a,b   Barry, Michael ^a   Curtin, Kay ^c   Beausang, Eamon ^a   Barry, Rupert ^a   Coyne, Imelda ^d  

^a ST JAMES S HOSPITAL   (Ireland)

^b LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^c Melanoma Support Ireland   (Ireland)

^d TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; CUTANEOUS MELANOMA; DATA COLLECTION METHOD; HUMAN; MOLECULARLY TARGETED THERAPY; NEOADJUVANT CHEMOTHERAPY; NEOADJUVANT THERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EID: 85043392228     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD012974     Document Type: Article

References (97)

1. Akbani R, Akdemir KC, Aksoy BA, Albert M, Ally A, Amin SB, et al. Genomic classification of cutaneous melanoma. Cell 2015; Vol. 161, issue 7:1681-96. [PUBMED: 26091043]
2. Algazi AP, Cha E, McCalmont T, Bastian BC, Hwang J, Pampaloni MH, et al. The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial. British Journal of Cancer 2015;112(8):1326-31. [PUBMED: 25867272]
3. Amaria RN, Reuben A, Cooper ZA, Wargo JA. Update on use of aldesleukin for treatment of high-risk metastatic melanoma. ImmunoTargets and Therapy 2015;4:79-89. [PUBMED: 27471714]
4. Andtbacka RHI, Chastain M, Li A, Shilkrut M, Ross MI. Phase 2, multicenter, randomised, open-label trial assessing efficacy and safety of talimogene laherparepvec (T-VEC) neoadjuvant treatment (tx) plus surgery vs surgery for resectable stage IIIB/C and IVM1a melanoma (MEL). Journal of Clinical Oncology 2015; Vol. 33, issue 15 Suppl:[Epub ahead of print]. [DOI: 10.1200/jco.2015.33.15_suppl.tps9094]
5. Balch CM, Gershenwald JE, Soong S, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. Journal of Clinical Oncology 2009;27(36):6199-206. [PUBMED: 19917835]
6. Barker CA, Postow MA. Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes. International Journal of Radiation Oncology, Biology, Physics 2014;88(5):986-97. [PUBMED: 24661650]
7. Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview. Oncology (Williston Park, N.Y.) 2009;23(6):488-96. [PUBMED: 19544689]
8. Braeuer RR, Watson IR, Wu CJ, Mobley AK, Kamiya T, Shoshan E, et al. Why is melanoma so metastatic?. Pigment Cell and Melanoma Research 2014;27(1):19-36. [PUBMED: 24106873]
9. Buzaid AC, Colome M, Bedikian A, Eton O, Legha SS, Papadopoulos N, et al. Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases. Melanoma research 1998;8(6):549-56. [PUBMED: 9918417]
10. Chandra RA, Wilhite TJ, Balboni TA, Alexander BM, Spektor A, Ott PA, et al. A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology 2015;4(11):e1046028. [PUBMED: 26451318]
11. COMET Initiative. Developing a Core Outcome Set (COS) for melanoma trials. www.comet-initiatve.org/studies/details/783 (accessed 28th April 2017).
12. Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, et al. Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer. Journal of Clinical Oncology 2015;33(34):4023-31. [PUBMED: 26392102]
13. Corrie P, Marshall A, Lorigan P, Gore ME, Tahir S, Faust G, et al. Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Final results for the AVAST-M trial. Journal of Clinical Oncology 2017;35(15 Suppl):9501. [DOI: 10.1200/JCO.2017.35.15_suppl.9501]
14. Veritas Health Innovation. Covidence Systematic Review Software. Melbourne: Veritas Health Innovation, 2017.
15. Cancer Research UK. General Cancer Information. www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/targeted-cancer-drugs/types/monoclonal-antibodies (accessed 29 January 2018).
16. National Cancer Institute. Common terminology criteria for adverse events, v4.0, 14 June 2010. evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference:5x7.pdf (accessed 14 November 2017).
17. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. New England Journal of Medicine 2005;353(20):2135-47. [PUBMED: 16291983]
18. Davar D, Tarhini AA, Kirkwood JM. Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach. Clinics in Dermatology 2013;31(3):237-50. [PUBMED: 23608443]
19. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; Vol. 417, issue 6892:949-54. [PUBMED: 12068308]
20. DermNET NewZealand. Dermoscopy. www.dermnetnz.org/topics/dermoscopy (accessed 27th December 2017).
21. Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U, ESMO Guidelines Committee. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2015;26(Suppl 5):v126-32. [PUBMED: 26314774]
22. Eggermont AMM, Suciu S, Testori A, Kruit WH, Marsden J, Punt C, et al. Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. European Journal of Cancer 2012;48(2):218-25. [PUBMED: 22056637]
23. Eggermont AMM, Spatz A, Robert C. Cutaneous melanoma. The Lancet 2014;383(9919):816-27. [PUBMED: 24054424]
24. Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. New England Journal of Medicine 2016;375(19):1845-55. [PUBMED: 27717298]
25. European Medicines Agency. Aldara - EMEA/H/C/000179 -II/0067. Annex I - Summary of product characteristics. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000179/WC500023122.pdf (accessed prior to 2 February 2018).
26. Food, Drug Administration. Guidance for Industry. Pathological complete response in neoadjuvant treatment of high-risk early stage breast cancer: use as an endpoint to support accelerated approval. www.fda.gov/downloads/drugs/guidances/ucm305501.pdf (accessed 20 July 2017).
27. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer 2015;136(5):E359-86. [PUBMED: 25220842]
28. Fields RC, Fleming MD, Gastman B, Gonzalez R, Johnson D, Joseph RW, et al. NCCN Clinical Practice Guidelines in Oncology Melanoma Version 1. 2017. www.nccn.org/store/login/login.aspx. National Comprehensive Cancer Network Inc, (accessed 20 July 2017).
29. Florin V, Desmedt E, Vercambre-Darras S, Mortier L. Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil. Investigational New Drugs 2012;30(4):1641-5. [PUBMED: 21748297]
30. Fruehauf J, Lutzky J, McDermott D, Brown CK, Meric JB, Rosbrook B, et al. Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma. Clinical Cancer Research 2011;17(23):7462-9. [PUBMED: 21976544]
31. Garbe C, Leiter U. Melanoma epidemiology and trends. Clinics in Dermatology 2009;27(1):3-9. [PUBMED: 19095149]
32. Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Bastholt L, et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guidelines-Update 2016. European Journal of Cancer 2016;63:201-17. [PUBMED: 27367293]
33. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200. Journal of Clinical Oncology 2007;25(12):1539-44. [PUBMED: 17442997]
34. Global Burden of Disease Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390(10100):1151-210. [PUBMED: 28919116]
35. Gnant M, Steger GG, Bartsch R. Pathological complete remission and long-term outcome-what do we know in 2016?. Lancet Oncology 2016;17(6):693-4. [PUBMED: 27179401]
36. Schünemann H, Brozek J, Guyatt G, Oxman A, editors and the GRADE Working Group, 2013. GRADE handbook for grading quality of evidence and strength of recommendations, the Cochrane Collaboration, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.
37. Evidence Prime Inc. GRADEpro Guideline Development Tool. McMaster University, 2015.
38. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012;380(9839):358-65. [PUBMED: 22735384]
39. Heise R, Amann PM, Ensslen S, Marquardt Y, Czaja K, Beer D, et al. Interferon alpha signalling and its relevance for the upregulatory effect of transporter proteins associated with antigen processing (TAP) in patients with malignant melanoma. PlosOne 2016;11(1):e0146325. [PUBMED: 26735690]
40. Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
41. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine 2010;363(8):711-23. [PUBMED: 20525992]
42. Hodi FS, Lee S, McDermott DF, Rao UN, Butterfield LH, Tarhini AA, et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomised clinical trial. JAMA 2014;312(17):1744-53. [PUBMED: 25369488]
43. Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncology 2016;17(11):1558-68. [PUBMED: 27622997]
44. Hoeller C, Jansen B, Heere-Ress E, Pustelnik T, Mossbacher U, Schlagbauer-Wadl H, et al. Perilesional injection of r-GM-CSF in patients with cutaneous melanoma metastases. Journal of Investigative Dermatology 2001;117(2):371-4. [PUBMED: 11511318 ]
45. Howard JH, Thompson JF, Mozzillo N, Nieweg OE, Hoekstra HJ, Roses DF, et al. Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Annals of surgical oncology 2012;19(8):2547-55. [PUBMED: 22648554]
46. Johnson DB, Menzies AM, Zimmer L, Eroglu Z, Ye F, Zhao S, et al. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. European Journal of Cancer 2015;51(18):2792-9. [PUBMED: 26608120]
47. Johnson AS, Crandall H, Dahlman K, Kelley MC. Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma. Journal of the American College of Surgeons 2015;220(4):581-93.e1. [PUBMED: 25797743]
48. Kang J, Demaria S, Formenti S. Current clinical trials testing the combination of immunotherapy with radiotherapy. Journal for ImmunoTherapy of Cancer 2016;4(51):1-20. [PUBMED: 27660705]
49. Kaufman HL, Andtbacka RHI, Collichio FA, Amatruda T, Senzer NN, Chesney J, et al. Primary overall survival (OS) from OPTiM, a randomised phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. Journal of Clinical Oncology 2014; Vol. 32, issue 15 Suppl:[Epub ahead of print]. [DOI: 10.1200/jco.2014.32.15_suppl.9008a]
50. Kim KB, Legha SS, Gonzalez R, Anderson CM, Johnson MM, Liu P, et al. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma research 2009;19(1):42-9. [PUBMED: 19430405]
51. Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, et al. BEAM: a randomised phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. Journal of Clinical Oncology 2012;30(1):34-41. [PUBMED: 22124101]
52. Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. Immunotherapy of cancer in 2012. CA: a cancer journal for clinicians 2012;62(5):309-35. [PUBMED: 22576456]
53. Kruijff S, Bastiaannet E, Brouwers AH, Nagengast WB, Speijers MJ, Suurmeijer AJH, et al. Use of S-100B to evaluate therapy effects during bevacizumab induction treatment in AJCC stage III melanoma. Annals of Surgical Oncology 2012;19(2):620-6. [PUBMED: 21861214]
54. Larkin J, Ascierto P, Dréno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. New England Journal of Medicine 2014;371(20):1867-76. [PUBMED: 25265494]
55. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. New England Journal of Medicine 2015; Vol. 373, issue 1:23-34. [PUBMED: 26027431]
56. Lacey CF, Armstrong LL, Goldman MP, Lance LL. Drug Information Handbook. 20th Edition. Ohio: American Pharmacists Association, 2011.
57. Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Annals of oncology: official journal of the European Society for Medical Oncology 2017;28(7):1631-9. [PUBMED: 28475671]
58. Long GV, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. New England Journal of Medicine 2017;377(19):1813-23. [PUBMED: 28891408]
59. McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncology 2014;15(3):323-32. [PUBMED: 24508103]
60. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. Journal of Clinical Oncology 2000;18(1):158-66. [PUBMED: 10623706]
61. Mocellin S, Lens MB, Pasquali S, Pilati P, Chiarion Sileni V. Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD008955.pub2]
62. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. British Medical Journal 2009;339:b2535. [PUBMED: 19622551]
63. Moschos SJ, Edington HD, Land SR, Rao UN, Jukic D, Shipe-Spotloe J, et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. Journal of Clinical Oncology 2006;24(19):3164-71. [PUBMED: 16809739]
64. National Cancer Institute. National Cancer Institute Dictionary of Cancer Terms. www.cancer.gov/publications/dictionaries/cancer-terms (accessed 18 August 2017).
65. National Institutes of Health. Stem Cell Information. www.stemcells.nih.gov/info/basics/1.htm (accessed 30 January 2018).
66. National Institutes of Health. Stem Cell Information. Glossary. www.stemcells.nih.gov/glossary.htm (accessed 30 January 2018).
67. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in medicine 1998;17(24):2815-34. [PUBMED: 9921604]
68. Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, Rossi CR, Mocellin S. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database of Systematic Reviews 2018, Issue 2. [DOI: 10.1002/14651858.CD011123.pub2]
69. Patel PM, Suciu S, Mortier L, Kruit WH, Robert C, Schadendorf D, et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). European Journal of Cancer 2011;47(10):1476-83. [PUBMED: 21600759]
70. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. New England Journal of Medicine 2011;365(26):2484-96. [PUBMED: 22204725]
71. Planchard D, Besse B, Groen HJM, Souquet PJ, Quoix E, Baik CS, et al. Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multi-centre phase 2 trial. Lancet Oncology 2016; Vol. 17, issue 7:984-93. [PUBMED: 27283860]
72. Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, et al. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America 2013;110(10):4015-20. [DOI: 10.1073/pnas.1216013110; PUBMED: 23431193]
73. Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. Journal of Clinical Oncology 2015;33(17):1974-82. [PUBMED: 25605845]
74. Prowell TM, Pazdur R. Pathological complete response and accelerated drug approval in early breast cancer. New England Journal of Medicine 2012;366(26):2438-41. [PUBMED: 22646508]
75. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
76. Reynders K, Illidge T, Siva S, Change JY, De Ruysscher D. The abscopal effect of local radiotherapy: using immunotherapy to made a rare event clinically relevant. Cancer Treatment Reviews 2015;41(6):503-10. [PUBMED: 25872878]
77. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncology 2015;16(8):908-18. [PUBMED: 26115796]
78. Ridolfi L, Ridolfi R. Preliminary experiences of intralesional immunotherapy in cutaneous metastatic melanoma. Hepato-gastroenterology 2002;49(44):335-9. [PUBMED: 11995445]
79. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New England Journal of Medicine 2011;364(26):2517-26. [PUBMED: 21639810]
80. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. New England Journal of Medicine 2015;372(1):30-9. [PUBMED: 25399551]
81. Sasse AD, Sasse EC, Clark LGO, Ulloa L, Clark OAC. Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD005413.pub2]
82. Saw R, Menzies A, Gruminski A, Nieweg AE, Shannon KF, Long GV, et al. Phase II study of neoadjuvant dabrafenib and trametinib for resectable stage IIIb/c BRAF V600 mutation positive melanoma. Journal of Clinical Oncology 2016;34(15 Suppl):9583. [DOI: 10.1200/JCO.2016.34.15_suppl.9583]
83. Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of Keynote-006. Journal of Clinical Oncology 2016;34(15 Suppl):9504. [DOI: 10.1200/JCO.2016.34.15_suppl.9504]
84. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. Journal of Clinical Oncology 2015;33(17):1889-94. [PUBMED: 25667295]
85. Si Z, Hersey P, Coates AS. Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF. Melanoma Research 1996;6(3):247-55. [PUBMED: 8819128]
86. Sullivan RJ, Flaherty KT. Resistance to BRAF-targeted therapy in melanoma. European Journal of Cancer 2013;49(6):1297-304. [PUBMED: 23290787]
87. Tarhini AA, Pahuja S, Kirkwood JM. Neoadjuvant therapy for high-risk bulky regional melanoma. Journal of Surgical Oncology 2011;104(4):386-90. [PUBMED: 21858833]
88. Thomas NE, Busam KJ, From L, Kricker A, Armstrong BK, Anton-Culver H, et al. Tumor-Infiltrating Lymphocyte Grade in Primary Melanomas Is Independently Associated With Melanoma-Specific Survival in the Population-Based Genes, Environment and Melanoma Study. Journal of Clinical Oncology 2013;31(33):4252-9. [PUBMED: 24127443]
89. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for oesophageal or junctional cancer. New England Journal of Medicine 2012;366(22):2074-84. [PUBMED: 22646630]
90. Varker KA, Biber JE, Kefauver C, Jensen R, Lehman A, Young D, et al. A randomised phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Annals of Surgical Oncology 2007;14(8):2367-76. [PUBMED: 17534686]
91. Wasif N, Bagaria SP, Ray P, Morton DL. Does metastasectomy improve survival in patients with stage IV melanoma? A cancer registry analysis of outcomes. Journal of Surgical Oncology 2011;104(2):111-5. [PUBMED: 21381040]
92. Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncology 2015;16(4):375-84. [PUBMED: 25795410]
93. Wheatley K, Ives N, Eggermont AMM, Kirkwood J, Cascinelli N, Markovic SN, et al. Interferon-alpha as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials. Journal of Clinical Oncology 2007;25(18 Suppl):8526. [DOI: 10.1200/jco.2007.25.18_suppl.8526]
94. Whiteman DC, Pavan WJ, Bastian BC. The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell and Melanoma Research 2011;24(5):879-97. [PUBMED: 21707960]
95. Whiteman DC, Green AC, Olsen CM. The growing burden of invasive melanoma: projections of incidence rates and numbers of new cases in six susceptible populations through 2031. Journal of Investigative Dermatology 2016;136(6):1161-71. [PUBMED: 26902923 ]
96. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New England Journal Of Medicine 2017; Vol. 377, issue 14:1345-56. [PUBMED: 28889792]
97. Zhao X, Subramanian S. Intrinsic resistance of solid tumors to immune checkpoint blockade therapy. Cancer Research 2017;77(4):817-22. [PUBMED: 28159861]